Background: Information regarding the use of glucose-lowering medications in patients with chronic kidney disease (CKD) is limited.

Study Design: Retrospective cohort study.

Setting & Participants: Medicare 5% random sample of patients with CKD with type 2 diabetes, 2007 to 2016.

Predictors: Study year, CKD stage, low-income subsidy status, and demographic characteristics (age, sex, race/ethnicity).

Outcomes: Trends in use of glucose-lowering medications.

Analytical Approach: Yearly cohorts of patients with CKD and type 2 diabetes were created. Descriptive statistics were used to report proportions of patients using glucose-lowering medications. To test overall trends in glucose-lowering medication classes, linear probability models with adjustment for age, sex, race/ethnicity, CKD stage, and low-income subsidy status were used.

Results: Metformin use increased significantly from 32.7% in 2007 to 48.7% in 2016. Use of newer classes of glucose-lowering medications increased significantly, including dipeptidyl peptidase 4 inhibitors (5.6%, 2007; 21.7%, 2016), glucagon-like peptide 1 receptor agonists (2.3%, 2007; 6.1%, 2016), and sodium-glucose cotransporter 2 inhibitors (0.2%, 2013; 3.3%, 2016). Newer insulin analogue use increased from 37.2% in 2007 to 46.3% in 2013 and then remained steady. Use of sulfonylureas, thiazolidinediones, older insulins (human regular and neutral protamine Hagedorn), α-glucosidase inhibitors, amylin mimetics, and meglitinides decreased significantly. Insulin was the most highly used single medication class. Insulin use was higher among low-income subsidy than among non–low-income subsidy patients. Combination therapy was less common as CKD stage increased.

Limitations: Patients with CKD and type 2 diabetes and the CKD stages were identified with diagnosis codes and could not be verified through medical record review. Our results may not be generalizable to younger patients with CKD with type 2 diabetes.

Conclusions: Use of metformin and newer glucose-lowering medication classes is increasing in patients with CKD with type 2 diabetes. We anticipate that percentages of patients with CKD using these newer agents will increase.

Diabetes is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease (ESKD). According to National Health and Nutrition Examination Survey data, the prevalence of CKD (stages 3 and 4) among US adults with diagnosed diabetes was 24.5% (27.1%-22.1%), and 4.9% (6.1%-4.1%) among those without diabetes in 2011 to 2014.

In addition to lifestyle modifications and psychosocial care, diabetes treatment includes pharmacologic approaches for glycemic control. Selecting effective and safe glucose-lowering medications for patients with CKD is challenging. Glucose-lowering medication pharmacokinetics can change, and some medications lose effectiveness as kidney function declines, necessitating dosage adjustments or discontinuation. Twelve classes of glucose-lowering medications are on the US market today (Table S1): biguanides, sulfonylureas, thiazolidinediones (TZDs), meglitinides/glinides, α-glucosidase inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitors, incretin mimetics/glucagon-like peptide 1 (GLP-1) receptor agonists, bile acid sequestrants, dopamine 2 agonists, amylin mimetics, and insulins.

Evidence supporting their effectiveness in patients with CKD is increasing. For example, Arjona Ferreira et al compared sitagliptin with glipizide regarding glucose lowering in patients with moderate to severe CKD and demonstrated the efficacy of sitagliptin in a randomized clinical trial. The EMPA-REG OUTCOME randomized controlled trial demonstrated lower rates of cardiovascular outcomes and kidney disease progression with empagliflozin than with placebo in patients with type 2 diabetes.

Information on the use of glucose-lowering medications in patients with CKD is limited. Our study aimed to: (1) update trends in the use of individual glucose-lowering medications and distinct therapeutic classes in patients with CKD with diabetes, (2) determine which monotherapies and combination therapies were commonly prescribed for patients with CKD with diabetes, and (3) examine patterns of glucose-lowering medication use in these patients by CKD stage.

METHODS

Study Population and Data Source

We evaluated an adult CKD population from the Medicare 5% random sample provided by the US Renal Data...
Recent data on the use of glucose-lowering medications in patients with chronic kidney disease (CKD) are lacking. We used Medicare 5% random sample data from 2007 to 2016 to examine trends in the use of individual glucose-lowering medications and distinct therapeutic classes in patients with CKD with type 2 diabetes. To test overall trends in glucose-lowering medication classes, we adjusted for age, sex, race/ethnicity, CKD stage, and low-income subsidy status. It is important to understand these trends and why they are occurring, especially given emerging data showing that sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists can reduce albuminuria and slow CKD progression.

**Study Design and Cohort Construction**

Yearly cohorts of patients with CKD and type 2 diabetes were created from January 1, 2007, to December 31, 2016. CKD and diabetes diagnoses were identified by International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification diagnosis codes. Eligible patients had 1 or more codes from inpatient services, home health, or skilled nursing facilities or 2 or more codes from physician claims or outpatient services on different claim dates within each cohort year for CKD (Table S2) and for type 2 diabetes (Table S3). Use of 2 outpatient claims has been shown to increase sensitivity and specificity compared with using only 1 claim for diabetes. Eligible patients who met the following criteria were included in the study: (1) had CKD and type 2 diabetes, 18 years or older, and alive through each cohort year; (2) enrolled in Medicare Parts A, B, and D for the entire year and not enrolled in a Medicare Advantage plan during any month; (3) did not develop ESKD during the year; and (4) received glucose-lowering medications.

**CKD Function Definition**

Kidney function was defined by CKD staging International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification diagnosis codes (Table S4). If multiple claims related to different CKD stages appeared in a cohort year, the most frequent stage (1-5) within the calendar year was used. If the same number of claims appeared for 2 or more stages, the highest severity stage was used. An unspecified stage code was used for patients without stage-specific codes.

**Glucose-Lowering Medications**

We used glucose-lowering medication names and classes provided in the American Diabetes Association (ADA) 2018 guideline “Pharmacologic Approaches to Glycemic Treatment” to identify medications from Part D claims data. Medication use was defined by at least 1 code for each medication class.

**Table 1. Characteristics of CKD Patients 18 Years or Older With Type 2 Diabetes Using Glucose-Lowering Medication, Medicare 5% CKD Claims, in 2007, 2012, and 2016**

|          | 2007     | 2012     | 2016     |
|----------|----------|----------|----------|
| Total    | 19,257   | 31,888   | 52,626   |
| Age, y   | 73.0 ± 11.0 | 73.9 ± 10.7 | 73.7 ± 10.2 |
| Age category, y |          |          |          |
| 18-44    | 336 (1.7%) | 441 (1.4%) | 576 (1.1%) |
| 45-64    | 3,014 (15.7%) | 4,407 (13.8%) | 6,612 (12.6%) |
| 65-74    | 6,757 (35.1%) | 10,960 (34.4%) | 20,379 (38.7%) |
| 75-84    | 6,618 (34.4%) | 11,121 (34.9%) | 17,716 (33.7%) |
| ≥85      | 2,532 (13.2%) | 4,959 (15.6%) | 7,344 (14.0%) |
| Sex      |           |          |          |
| Male     | 7,992 (41.5%) | 14,243 (44.7%) | 25,744 (48.9%) |
| Female   | 11,265 (58.5%) | 17,645 (55.3%) | 26,882 (51.1%) |
| Race/ethnicity |         |          |          |
| White    | 14,044 (72.9%) | 23,443 (73.5%) | 40,148 (76.3%) |
| Black    | 3,376 (17.5%) | 5,217 (16.4%) | 7,516 (14.3%) |
| Native American | 162 (0.8%) | 217 (0.7%) | 333 (0.6%) |
| Asian    | 534 (2.8%) | 1,072 (3.4%) | 1,521 (2.9%) |
| Hispanic | 832 (4.3%) | 1,296 (4.1%) | 1,679 (3.2%) |
| Other    | 290 (1.5%) | 565 (1.8%) | 956 (1.8%) |
| Unknown  | 19 (0.1%) | 78 (0.2%) | 473 (0.9%) |
| Low-income subsidy status |           |          |          |
| Non–low-income subsidy | 7,891 (41.0%) | 14,756 (46.3%) | 31,101 (59.1%) |
| Low-income subsidy | 11,366 (59.0%) | 17,132 (53.7%) | 21,525 (40.9%) |
| CKD stage |          |          |          |
| 1        | 497 (2.6%) | 686 (2.2%) | 995 (1.9%) |
| 2        | 1,111 (5.8%) | 2,197 (6.9%) | 4,343 (8.3%) |
| 3        | 5,484 (28.5%) | 14,483 (45.4%) | 26,933 (50.5%) |
| 4        | 1,857 (9.6%) | 3,005 (9.4%) | 3,815 (7.2%) |
| 5        | 160 (0.8%) | 160 (0.5%) | 193 (0.4%) |
| Unknown/ unspecified | 10,148 (52.7%) | 11,357 (35.6%) | 16,687 (31.7%) |

**NOTE:** Values for age as a continuous variable are given as mean ± standard deviation. Abbreviation: CKD, chronic kidney disease.
Part D–covered medication during the calendar year. Use of these agents individually and within each therapeutic class was reported. We also reported on monotherapy for each glucose-lowering medication class. To identify combination use of multiple glucose-lowering medication classes, information on days’ supply was used. Use of more than 1 glucose-lowering medication class overlapping for at least 2 continuous months was defined as combination therapy.

**Statistical Analysis**

We used descriptive statistics to report proportions of individuals using any glucose-lowering medication or class by calendar year. To test overall trends in glucose-lowering medication classes, linear probability regression models with adjustment for age, sex, race/ethnicity, CKD stage, and low-income subsidy status were used. To account for repeated observations (calendar years) per patient, generalized estimating equations were used to fit the model. For 2016, we report more detailed information on proportions of patients receiving monotherapy or combination therapy by CKD stage. All analyses were performed using SAS, version 9.4 (SAS Institute).

The University of Minnesota Institutional Review Board approved the study (IRB ID: STUDY00000991). Participants’ informed consent was not required.

**RESULTS**

Final sample sizes of patients meeting inclusion criteria and using glucose-lowering medications ranged from 19,257 in 2007 to 52,626 in 2016. In 2016, a total of 21% of patients with CKD and type 2 diabetes had no prescriptions for glucose-lowering medications. A Consolidated Standards of Reporting Trials (CONSORT) diagram for 2016 patients is provided in Fig 1. In 2016, a total of 86.3% were 65 years or older. Distributions of age and race/ethnicity were similar across yearly cohorts (Table 1). The proportion of patients at stage 3 CKD in 2016 (50.5%) was higher than in 2007 (28.5%) or 2012 (45.4%). The proportion of patients with low-income subsidy status in 2016 was lower than in 2007 or 2012 (Table 1).

**Trends in Use of Glucose-Lowering Medication Classes**

Several glucose-lowering medication classes showed statistically significant increases in use trends from 2007 to 2016, including metformin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and newer insulin analogues (Fig 2;
Table S5). Metformin use increased from 32.7% in 2007 to 48.7% in 2016. Use of newer classes of glucose-lowering medication increased sharply, including DPP-4 inhibitors (5.6% in 2007, 21.7% in 2016), GLP-1 receptor agonists (2.3% in 2007, 6.1% in 2016), and SGLT2 inhibitors (0.2% in 2013, 3.3% in 2016). Use of newer insulin analogues (aspart, lispro, glulisine, detemir, glargine, and degludec) increased from 37.2% in 2007 to 46.3% in 2013 and then remained steady. Use of sulfonylureas, TZDs, older insulins, α-glucosidase inhibitors, amylin mimetics, and meglitinides decreased significantly. Sulfonylurea use declined from 50.1% in 2007 to 37.9% in 2016, and TZD use, from 32.2% in 2007 to 7.0% in 2016. Use of older insulins (human regular and neutral protamine Hagedorn [NPH]) declined from 26.4% in 2007 to 7.1% in 2016. Trends in all glucose-lowering medication classes are shown in Fig 2.

We also examined trends in glucose-lowering medication classes by age (<65 and ≥65 years). Patients younger than 65 years were mainly people with disabilities. Trends were similar between these age groups. However, use of sulfonylureas, newer insulin analogue insulins, or older insulins (28.6%, 59.9%, and 10.1% in 2016, respectively) among patients younger than 65 years differed from use among patients 65 years or older (39.3%, 41.5%, and 6.6% in 2016, respectively).

**Figure 2.** Trends in use of glucose-lowering medication classes among patients with chronic kidney disease with type 2 diabetes between 2007 and 2016. Newer insulin analogues include aspart, lispro, glulisine, detemir, glargine, and degludec. Older insulins include human regular and neutral protamine Hagedorn (NPH). Abbreviations: DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1; SGLT2, sodium-glucose cotransporter 2.

**Trends in Use of Specific Glucose-Lowering Medications**

Sitagliptin was the most commonly prescribed DPP-4 inhibitor; use increased from 5.6% in 2007 to 15.0% in 2016 (Fig 3A). Use of linagliptin (approved in 2011) increased from 0.1% in 2011 to 6.0% in 2016. Compared with other GLP-1 receptor agonists, use of liraglutide (approved in 2010) increased more (0.3% in 2010 to 3.6% in 2016) and use was higher in 2016. Use of SGLT2 inhibitors (canagliflozin, empagliflozin, or dapagliflozin) remained very low in 2016 but was increasing. For example, use of canagliflozin (approved in 2013) increased from 0.2% in 2013 to 2.4% in 2016. Except for glimepiride, which showed an increasing trend from 13.2% in 2007 to 16.2% in 2016, use of other sulfonylureas decreased (eg, glyburide use decreased from 16.5% to 2.2% from 2007 to 2016; Fig 3B). A large decline in the use of TZDs occurred from 2007 to 2016; rosiglitazone was essentially unused by 2012.

Use of newer analogue insulin therapy increased, especially insulin detemir (2.4% in 2007 and 11.7% in 2016), while NPH insulin use declined from 18.9% in 2007 to 4.8% in 2016, and regular insulin, from 21.9% in 2007 to 5.6% in 2016 (Fig 3C).
Use of Glucose-Lowering Medication Classes by CKD Stage

In 2016, percentages of patients with CKD with type 2 diabetes receiving insulin increased as CKD stage increased: 41% at stages 1-2 and 66% at stages 4-5. Metformin use decreased as CKD stage increased; 63% at stages 1-2 and 15% at stages 4-5. Use of DPP-4 inhibitors and GLP-1 receptor agonists was similar across CKD stages (Fig 4). Single and dual combination use of glucose-lowering medications was 49.6% and 39.9% among patients with CKD in 2016, respectively (Fig S1). The proportion of patients using 2 or more glucose-lowering medication classes decreased as CKD stage increased. Triple combination therapy was used in 16% and 9% of patients with CKD stages 1-2 and stages 4-5, respectively; quadruple combination therapy was uncommon: 4% at stages 1-2 and 1% at stages 4-5 (Fig 5).

Among patients with CKD with diabetes who received a single glucose-lowering medication class in 2016, the most highly used class was insulin (41%; Table 2). The most highly used dual combination therapies in 2016 were metformin, sulfonylurea (second generation), and thiazolidinedione use; and (C) insulin use. Abbreviation: nph, neutral protamine Hagedorn.

**DISCUSSION**

We present use patterns of glucose-lowering medications among patients with CKD based on Medicare data. Use of
Two recent analyses of glucose-lowering medication class use in the general population are available. Sumarsono et al.\(^\text{10}\) published trends in and expenditures of glucose-lowering medications among US Medicare beneficiaries, 2012 to 2017. Metformin use increased during the study time frame and was the most commonly prescribed glucose-lowering medication,
Table 2. Use of Glucose-Lowering Medication Classes Among CKD Patients With Type 2 Diabetes Using Monotherapy, in 2016

| Class                     | Number of Patients (Prevalence %) |
|--------------------------|-----------------------------------|
| Insulins                 | 10,687 (41.0%)                    |
| Metformin                | 8,303 (31.8%)                     |
| Sulfonylureas            | 4,602 (17.6%)                     |
| DPP-4 inhibitors         | 1,519 (5.8%)                      |
| Thiazolidinediones       | 418 (1.6%)                        |
| Meglitinides             | 233 (0.9%)                        |
| GLP-1 receptor agonists  | 179 (0.7%)                        |
| Bile acid sequestrants   | 68 (0.3%)                         |
| SGLT2 inhibitors         | 50 (0.2%)                         |
| α-Glucosidase inhibitors | 17 (0.1%)                         |
| Amylin mimetics          |                                   |
| Dopamine-2 agonists      |                                   |

Note: Number of patients with CKD with type 2 diabetes using monotherapy = 26,081.
Abbreviations: CKD, chronic kidney disease; DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1; SGLT2, sodium-glucose cotransporter 2.

whereas amylin analogues were the least commonly prescribed class.10

Using Medical Expenditure Panel Survey (MEPS) data from 2008 to 2015, Raval and Vyas11 examined trends in glucose-lowering medication use among US individuals with diabetes and showed similar results. Use of metformin increased from 47.8% in 2008 to 59.0% in 2015, use of TZDs and sulfonylureas decreased, and use of DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors increased.11 We show use patterns of glucose-lowering medication classes among patients with CKD similar to those in the general population, except that insulin was the most commonly used glucose-lowering medication class in patients with CKD versus metformin in the general population. We noted a greater increase in DPP-4 inhibitor use among patients with CKD (8.4% to 21.5%) from 2008 to 2015 compared with the general population (6.2% to 12.4%) in the MEPS study. Regarding multiclass therapy use in the general population, the MEPS study reported that in 2015, the 2 most common dual combination therapies were metformin and sulfonylureas and metformin and insulin; the 2 most common triple combination therapies were metformin, sulfonylureas, and DPP-4 inhibitors and metformin, sulfonylureas, and insulin.11 We observed the same common patterns of combination therapies in patients with CKD in 2016.

We observed an increase in metformin use in patients with CKD. In 2016, there were 63%, 41%, and 65% of patients at CKD stages 1-2, stage 3, and unspecified stage with diabetes, respectively, who used metformin. Metformin is inexpensive and effectively decreases plasma glucose levels.3 The United Kingdom Prospective Diabetes Study demonstrated a reduced risk for cardiovascular events and death with metformin compared with sulfonylureas, insulin, or diet restriction among overweight patients with type 2 diabetes.12 However, metformin is mainly eliminated by the kidneys and is associated with risk for lactic acidosis, which has in the past limited its use in patients with CKD. In recent years, several observational studies have shown that metformin can be safely used in patients with mild to moderate kidney function.13-15 In 2016, the US Food and Drug Administration (FDA) requested a labeling change regarding metformin use in patients with reduced kidney function.16 Accordingly, the ADA and European Association for the Study of Diabetes 2019 guidelines recommend that metformin be considered as the first-line treatment for patients with type 2 diabetes with estimated glomerular filtration rates (eGFRs) of 30 to 60 mL/min/1.73 m2.1,17 Consistent with the FDA label change, ADA guidelines state that metformin is contraindicated in patients with eGFRs < 30 mL/min/1.73 m2,1,17,18 Our results showed 15% metformin use in 2016 among patients with CKD stages 4-5; further investigation into the effectiveness and safety of metformin therapy in severe CKD is warranted.

We found a rapid increase in the use of several new therapeutic classes, including DPP-4 inhibitors (first approval, 2006, sitagliptin), GLP-1 receptor agonists (2005, exenatide), and SGLT2 inhibitors (2013, canagliflozin). Much higher DPP-4 inhibitor use (21.7%) than GLP-1 receptor agonist (6.1%) or SGLT2 inhibitor (3.3%) use in 2016 was unsurprising due to their being on the market longer. DPP-4 inhibitor use was even higher (24%) among patients with CKD stages 4-5, driven by sitagliptin use. This trend was most likely due to clinician comfort with sitagliptin, given pharmacokinetic and safety studies in patients with CKD showing that a reduced dose was effective and safe even in patients receiving hemodialysis.10 We showed that sitagliptin use increased from 5.6% in 2007 to 15.6% in 2013, then remained relatively constant. Linagliptin use also increased from 0.1% in 2011 to 6% in 2016. Linagliptin is eliminated predominantly through the bile and hence does not require dose adjustment for patients with CKD.14 In contrast, all other drugs in this class (sitagliptin, saxagliptin, and alogliptin) are excreted mainly by the kidneys; ADA guidelines recommend dose adjustments in patients with CKD.1,18

The SGLT2 inhibitor class is the newest class of oral glucose-lowering medications. In March 2008, the FDA issued new guidance on the evaluation of cardiovascular risk during development of new glucose-lowering medications.22 Following the FDA guidance, recent glucose-lowering medication clinical trials include cardiovascular and kidney-related outcomes. The EMPA-REG OUTCOME clinical trial demonstrated lower rates of cardiovascular events and lower risk for incident or worsening nephropathy (progression to macroalbuminuria, doubling of serum creatinine level, initiation of kidney-replacement therapy, or death from kidney disease) for empagliflozin than for placebo in patients with type 2 diabetes at high risk for cardiovascular events.5,6,23 Recently, the CANVAS trial showed that canagliflozin reduced rates of the cardiovascular composite outcome, albuminuria progression, and
Kidney composite outcome compared with placebo among 10,142 patients with type 2 diabetes and high cardiovascular risk.\cite{24} The DECLARE-TIMI 58 trial evaluated the cardiovascular safety of dapagliflozin in patients with type 2 diabetes and cardiovascular risk.\cite{25} Compared with other SGLT2 inhibitor trials in which the primary outcome was cardiovascular events, the CREDENCE trial was designed to assess the effects of canagliflozin primarily on kidney outcomes in patients with type 2 diabetes and albuminuric CKD.\cite{26} The current canagliflozin label recommends use in patients with an eGFR down to 30 mL/min/1.73 m² based on the CREDENCE trial data. The current empagliflozin and dapagliflozin labels suggest avoiding use in patients with an eGFR below 45 mL/min/1.73 m². We anticipate that percentages of patients with CKD using these agents will greatly increase above the 2016 level, considering positive trial results.

Most current GLP-1 receptor agonists are injectable. The first oral GLP-1 receptor agonist, semaglutide, was approved in 2019 by the FDA.\cite{27} Our data showed that liraglutide and dulaglutide use gradually increased since approval in 2010 and 2014, respectively. LEADER clinical trial results showed a significant benefit with liraglutide compared with placebo on cardiovascular events and composite kidney outcomes of new-onset persistent macroalbuminuria, persistent doubling of serum creatinine level, ESKD, or death due to kidney disease.\cite{28,29} The AWARD-7 clinical trial assessed the efficacy and safety of dulaglutide among patients with type 2 diabetes and CKD stages 3-4. Compared with insulin glargine, the efficacy of dulaglutide was similar in glycemia control, with a lower rate of hypoglycemia, smaller decline in eGFR, and greater reduction in albuminuria.\cite{30} Use of these agents will likely increase in patients with CKD, considering data from these recent trials.

We observed a significant decrease in TZD use from 2008 to 2016, initially due to study reports and safety warnings issued by the FDA with rosiglitazone. In September 2010, the FDA announced increased cardiovascular risks in patients treated with rosiglitazone.\cite{31} Despite FDA action that removed the prescribing and dispensing restrictions for rosiglitazone in 2013 based on new data,\cite{32} rosiglitazone use remained almost nonexistent. In December 2016, the FDA announced that pioglitazone was associated with an increased risk for bladder cancer,\cite{33} but use has remained steady at 7.5% since 2013. We observed that sulfonylurea use significantly decreased from 2007 to 2016. Specifically, glyburide use decreased from 16.5% in 2007 to 2.2% in 2016. However, glimepiride use consistently increased from 13.2% in 2007 to 16.2% in 2016, and glipizide use was relatively constant at ∼21%. The second-generation agents (glyburide, glimepiride, and gliclazide) have largely replaced first-generation drugs (chlorpropamide, tolazamide, and tolbutamide) in the general population due to lower risk for hypoglycemia. Glyburide is metabolized in the liver and excreted by the kidneys and bile, ∼50% by each route. Some metabolites, which have hypoglycemic activity, can accumulate in patients with CKD.\cite{18} Glyburide is not recommended for patients with CKD.\cite{3} An observational study by Roumie et al\cite{35} compared metformin monotherapy treatment with sulfonylureas in patients with diabetes and reduced kidney function (eGFRs < 60 mL/min/1.73 m²) and showed that sulfonylureas were associated with higher risk for major adverse cardiovascular events. ADA 2019 guidelines recommend metformin as the preferred first-line diabetes treatment in patients with CKD, depending on eGFR, and the best noninsulin added treatment to initial therapy is an SGLT2 inhibitor or GLP-1 receptor agonist due to their cardiovascular and kidney-related benefits.\cite{19}

Despite FDA action that removed the prescribing and dispensing restrictions for rosiglitazone in 2013 based on new data,\cite{32} rosiglitazone use remained almost nonexistent. In December 2016, the FDA announced that pioglitazone was associated with an increased risk for bladder cancer,\cite{33} but use has remained steady at 7.5% since 2013. We observed that sulfonylurea use significantly decreased from 2007 to 2016. Specifically, glyburide use decreased from 16.5% in 2007 to 2.2% in 2016. However, glimepiride use consistently increased from 13.2% in 2007 to 16.2% in 2016, and glipizide use was relatively constant at ∼21%. The second-generation agents (glyburide, glimepiride, and gliclazide) have largely replaced first-generation drugs (chlorpropamide, tolazamide, and tolbutamide) in the general population due to lower risk for hypoglycemia. Glyburide is metabolized in the liver and excreted by the kidneys and bile, ∼50% by each route. Some metabolites, which have hypoglycemic activity, can accumulate in patients with CKD.\cite{18} Glyburide is not recommended for patients with CKD.\cite{3} An observational study by Roumie et al\cite{35} compared metformin monotherapy treatment with sulfonylureas in patients with diabetes and reduced kidney function (eGFRs < 60 mL/min/1.73 m²) and showed that sulfonylureas were associated with higher risk for major adverse cardiovascular events. ADA 2019 guidelines recommend metformin as the preferred first-line diabetes treatment in patients with CKD, depending on eGFR, and the best noninsulin added treatment to initial therapy is an SGLT2 inhibitor or GLP-1 receptor agonist due to their cardiovascular and kidney-related benefits.\cite{19}

### Table 3. Use of Common Glucose-Lowering Medication Classes Combination Therapy Among Patients With CKD With Type 2 Diabetes Using More Than 1 Glucose-Lowering Medication Class, in 2016

| Combination Therapy                          | Number (Percentage) |
|---------------------------------------------|---------------------|
| Metformin + sulfonylurea                    | 5,543 (20.1%)       |
| Metformin + insulin                        | 3,859 (14.5%)       |
| Sulfonylurea + insulin                      | 2,728 (10.3%)       |
| Metformin + DPP-4 inhibitor                 | 2,060 (7.8%)        |
| Sulfonylurea + DPP-4 inhibitor              | 1,801 (6.8%)        |
| DPP-4 inhibitor + insulin                   | 1,710 (6.4%)        |
| Metformin + sulfonylurea + DPP-4 inhibitor  | 1,432 (5.4%)        |
| Metformin + sulfonylurea + insulin          | 1,368 (5.2%)        |
| GLP-1 receptor agonist + insulin            | 818 (3.1%)          |

**NOTE:** Use of combination therapy ≥ 3% shown. Number of patients with CKD with type 2 diabetes using more than 1 glucose-lowering medication class = 26,545.

Abbreviations: CKD, chronic kidney disease; DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1.
stage 3 or higher (eGFR ≥ 30 mL/min/1.73 m²), metformin is the recommended first-line treatment choice because of its safety, low cost, and potential cardiovascular benefits. An SGLT2 inhibitor is recommended in the glucose-lowering treatment regimen. In patients who have not achieved individualized glycemic targets despite use of metformin and an SGLT2 inhibitor or who are unable to use those medications, a GLP-1 receptor agonist is recommended.19

Distribution of CKD stage varied across our yearly cohorts. CKD stage-specific diagnosis codes (585.X) were first introduced in 2006 and have been used increasingly. In 2007, CKD stage-specific codes accounted for only 49% of all CKD diagnosis codes, but for 68% in 2015.40 We conducted trends analysis of glucose-lowering medication classes with adjustment for CKD stage.

Our study has several strengths. We provide a comprehensive picture and contemporary trends in use patterns of glucose-lowering medications in older adults with CKD and type 2 diabetes enrolled in Medicare Part D. We use actual medication claims dispensing records rather than other data sources that might measure prescribing patterns. This is the first evaluation of the use of combination therapy and glucose-lowering medications by CKD stage.

Our analysis also has several limitations. Clinical characteristics were measured based on administrative claims. In our study, patients with CKD and type 2 diabetes and the CKD stages were identified with diagnosis codes and could not be verified through medical record review or laboratory values. Second, information provided in Part D claims is based on prescription claims. How patients take these prescriptions is unknown. Last, our analysis cohort consisted of patients with CKD enrolled in Medicare Part D; use patterns may differ for patients enrolled in non—Part D prescription plans or Medicare Advantage plans or other types of health insurance. The Medicare data set does not include patients younger than 65 years, except people with disabilities, and we excluded patients with ESKD.

Our study results can help providers understand current use patterns of glucose-lowering medications in patients with CKD. Further investigations are needed to examine the impact of newly published clinical trial results on use patterns of glucose-lowering medications in patients with CKD and assess health care outcomes related to the safety and effectiveness of glucose-lowering medications in CKD using real-world data.

**SUPPLEMENTARY MATERIAL**

Figure S1. Percent using monotherapy and combination therapy among chronic kidney disease patients with type 2 diabetes using glucose-lowering medications in 2016.

Figure S2. Trend of insulins use among chronic kidney disease patients with type 2 diabetes from 2007 to 2016, by low-income subsidy status.

Table S1. Glucose-lowering medication classes and medications

Table S2. ICD-9/10-CM diagnosis codes for chronic kidney disease

Table S3. ICD-9/10-CM diagnosis codes for diabetes

Table S4. ICD-9/10-CM diagnosis codes for chronic kidney disease stages

Table S5. GEE model estimation for change in overall trends of glucose-lowering medication classes from 2007 to 2016 in CKD patients with type 2 diabetes

**REFERENCES**

1. Fowler MJ. Microvascular and macrovascular complications of diabetes. *Clin Diabetes*. 2008;26(2):77-82.

2. Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System—United States. Advanced stage CKD (stages 3 and 4) Prevalence by year and diabetes status in U.S. adults. Accessed February 14, 2020. https://ncdd.cdc.gov/CKD/detail.aspx?Num=Q702#refreshPosition

3. American Diabetes Association. B. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2018. *Diabetes Care*. Accessed February 14, 2020. https://care.diabetesjournals.org/content/41/Supplement_1/S73

4. Arjona Ferreira JC, Marre M, Barzilai N, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. *Diabetes Care*. 2013;36(5):1067-1073.

5. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2015;373(22):2117-2128.

6. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med*. 2016;375(4):323-334.
18. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment. \textit{Am J Med}. 1999;14(6):270-277.

9. Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, Bean MC. Identifying persons with diabetes using Medicare claims data. \textit{Am J Med Qual}. 1999;14(6):270-277.

10. Sumarsono A, Everett BM, McGuire DK, et al. Trends in aggregate use and associated expenditures of antihyperglycemic therapies among US Medicare beneficiaries between 2012 and 2017. \textit{JAMA Intern Med}. 2020;180(1):141-144.

11. Raval AD, Vyas A. National trends in diabetes medication use in the United States: 2008 to 2015. \textit{J Pharm Pract}. 2018;33(4):433-442.

12. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year follow-up of intensive glucose control in type 2 diabetes. \textit{N Engl J Med}. 2008;359(15):1577-1589.

13. Rachmani R, Slavachevski I, Levi Z, Zadok B-S, Kedar Y, Ravid M. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. \textit{Eur J Intern Med}. 2002;13(7):428-433.

14. Scarpello JH, Howlett HC. Metformin therapy and clinical uses. \textit{Diab Vasc Dis Res}. 2008;5(3):157-167.

15. Klachko D, Whaley-Connell A. Use of metformin in patients with kidney and cardiovascular diseases. \textit{Cardiovasc Med}. 2011;1(2):87-95.

16. FDA Drug Safety Podcast. FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. FDA. \textit{February}. 2019. http://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-drug-safety-podcast-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain. Accessed February 14, 2020.

17. Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). \textit{Diabetes Care}. 2020;43(2):487-493.

18. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment. \textit{Diabetes Care}. 2017;40(suppl 1):S64-S74.

19. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2019. \textit{Diabetes Care}. 2019;42(suppl 1):S90-S102.

20. Arjona Ferreira JC, Corry D, Mogensen CE, et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. \textit{Am J Kidney Dis}. 2013;61(4):579-587.

21. Kanasaki K. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. \textit{Clin Sci (Lond)}. 2018;132(4):489-507.

22. FDA guidance for industry: diabetes mellitus. Published December 19, 2008. Accessed April 20, 2020. https://www.federalregister.gov/documents/2008/12/19/EB-30086/guidance-for-industry-on-diabetes-mellitus-evaluating-cardiovascular-risk-in-new-antidiabetic.

23. Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. \textit{Circulation}. 2018;137(2):119-129.

24. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. \textit{N Engl J Med}. 2017;377(7):644-657.

25. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. \textit{N Engl J Med}. 2019;380(4):347-357.

26. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. \textit{N Engl J Med}. 2019;380(24):2295-2306.

27. FDA FDA. approves first oral GLP-1 treatment for type 2 diabetes. Published September 20, 2019. http://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes. Accessed February 14, 2020.

28. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular and renal outcomes in type 2 diabetes. \textit{N Engl J Med}. 2016;375(4):311-322.

29. Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. \textit{N Engl J Med}. 2017;377(9):839-848.

30. Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. \textit{Lancet Diabetes Endocrinol}. 2018;6(8):605-617.

31. FDA Drug Safety Communication. Avandia (rosiglitazone) labels now contain updated information about cardiovascular risks and use in certain patients. http://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-avandia-rosiglitazone-labels-now-contain-updated-information-about. June 2019. Accessed February 14, 2020.

32. FDA Drug Safety Communication. FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines. http://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-requires-removal-some-prescribing-and-dispensing-restrictions. June 2019. Accessed February 14, 2020.

33. FDA Drug Safety Podcast. updated FDA review concludes that use of pioglitazone may be linked to an increased risk of bladder cancer. http://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-drug-safety-podcast-update-of-pioglitazone-may-be-linked-increased-risk. February 2019. Accessed February 14, 2020.

34. Sola D, Rossi L, Schianca GPC, et al. Sulfonylureas and their use in clinical practice. \textit{Arch Med Sci}. 2015;11(4):840-848.

35. Roumie CL, Chipman J, Min JY, et al. Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function. \textit{JAMA}. 2019;322(12):1167-1177.

36. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues containing diabetes medicines. \textit{Diabetes Care}. 2003;26(2):502-509.

37. Owens DR, Taylor L, Mullins P, Landgraf W. Patient-level meta-analysis of efficacy and hypoglycemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral anti-diabetes therapy. \textit{Diabetes Res Clin Pract}. 2017;124:57-65.

38. Ruggenenti P, Flores C, Aros C, et al. Renal and metabolic effects of insulin lispro in type 2 diabetic patients with overt nephropathy. \textit{Diabetes Care}. 2003;26(2):502-509.

39. Kidney Disease: Improving Global Outcomes. KDIGO diabetes guidelines in 2020. Accessed August 5, 2020. https://kidigo.org/guidelines/diabetes-ckd/.

40. US Renal Data System. Chapter 2: Identification and care of patients with CKD. In: USRDS 2017 Annual Data Report. \textit{Am J Kidney Dis}. 2018;71(3):S31-S46.
Conclusion: Use of metformin and newer glucose-lowering medication classes is increasing in CKD patients, including in CKD stages 3 and 4, with type 2 diabetes.

| Cohort and Study Design | Findings | Decreased use of |
|-------------------------|----------|-----------------|
| Retrospective observational cohort study | Increased use of | Decreased use of |
| n = 19,257 (2007) n = 52,626 (2016) | Metformin | Sulfonylureas |
| Medicare 5% random sample | 32.7% (2007) 48.7% (2016) | Thiazolidinediones |
| Chronic kidney disease (CKD) | Newer classes of glucose-lowering medications | Old insulin analogs |
| Type 2 diabetes | DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors | Insulin |
| Jan 2007 – Dec 2016 | Newer insulin analogs | Regular, NPH |
| | Aspart, Lispro, Glulisine, Degludec, Insulin | | |
| | 37.2% (2007) 46.3% (2013) | Meglitinide |
| | | Combination therapy |
| | Insulin | Less commonly used as CKD stage progressed |
| | Most highly used single medication class (41%) | Use higher among low-income subsidy status patients |
| | | | |

Reference: Zhao JZ, Weinhandl ED, Carlson AM, et al. Glucose-Lowering Medication use in CKD: Analysis of US Medicare Beneficiaries between 2007 and 2016. Kidney Medicine, 2021.